Long Term Safety Study of PRALUENT

Stopped early · Phase 4

Conditions studied: Heterozygous Familial Hypercholesterolemia, Non-familial Hypercholesterolemia

In brief

The primary objective of the study was to evaluate the long term safety of PRALUENT in participants with heterozygous familial hypercholesterolemia (heFH) or non-familial hypercholesterolemia (FH) participants at high or very high cardiovascular risk who completed the neurocognitive function study R727-CL-1532 (NCT02957682). The secondary objectives of the study were: * To evaluate the effect of PRALUENT on low-density lipoprotein cholesterol (LDL-C) * To evaluate the effect of PRALUENT on other lipid parameters * To evaluate the effect of PRALUENT on gonadal steroid hormones

Key facts

Study ID
NCT03694197
Run by
Regeneron Pharmaceuticals
People needed
1389
Starts
2018-09-28
Expected to finish
2020-04-08
Last updated by the study team
2021-06-15

Who can join

Age: 40 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.